Biotechnological companies using AI
Qiagen N.V. (NYSE: QGEN) outlined its 2026 priorities at the J.P. Morgan Healthcare Conference, emphasizing plans to expand its five core growth pillars, integrate the Parse Biosciences acquisition for single--cell analysis, and pursue automation, AI, and targeted M&A to achieve $2.00 billion in pillar sales by 2028. This announcement, made earlier this week, follows a special US$2.29 cash dividend with an ex--dividend date of January 8, 2026.